BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:iRegene Therapeutics Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies iRegene Therapeutics Co.\, Ltd.'s
  drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07028632-1742@assetmemo.bio
DTSTAMP:20261121T005946Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:NouvNeu001: Phase 2 readout est. (NCT07028632)
DESCRIPTION:NouvNeu001\, phase 2\, Parkinson's Disease.\nStudy: The Safety\
 , Feasibility and Efficacy of NouvNeu001 for Parkinson's Disease\nEstimate
 d primary completion: December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nouvneu001#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07028632
URL:https://assetmemo.bio/drug/nouvneu001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102342-1742@assetmemo.bio
DTSTAMP:20261121T005946Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:NouvNeu001: Phase 1/2 readout est. (NCT07102342)
DESCRIPTION:NouvNeu001\, phase 1/2\, Parkinson's Disease.\nStudy: This Clin
 ical Trial is Designed to Evaluate the Safety\, Tolerability\, Feasibility
  and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cel
 ls Injection) in Patients With Parkinson's Disease.\nEstimated primary com
 pletion: September 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nouvneu001#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07102342
URL:https://assetmemo.bio/drug/nouvneu001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
